Latest Regulatory Filings News

Zelira Therapeutics has received a $1.07 million cash refund under Australia’s R&D Tax Incentive Scheme, reinforcing its funding for ongoing clinical trials and product development. The company has also repaid a prior loan advanced against this claim, positioning it for continued growth in cannabinoid-based medicines.

Metcash Limited has responded to an ASX query regarding the late filing of a director’s interest notice, attributing the delay to an administrative oversight and outlining plans to enhance compliance processes.

Mesoblast has achieved a landmark FDA approval for RYONCIL, the first allogeneic mesenchymal stromal cell therapy, driving strong commercial momentum and advancing a robust pipeline targeting inflammatory diseases.

Dusk Group Limited has addressed an ASX compliance query regarding the delayed disclosure of a director’s interest change, attributing the lapse to an administrative oversight while reaffirming its commitment to regulatory compliance.

Embark Early Education has revised the timeline for its conditional takeover bid of Mayfield Childcare, delaying key regulatory filings into early 2026.

DroneShield Limited has clarified the recent exercise and sale of shares by its directors following performance option vesting, alongside addressing an erroneous contract announcement that was later withdrawn. The company also outlined steps to enhance compliance with ASX continuous disclosure and trading policies.

Stealth Group Holdings has explained the late filing of a director’s interest notice as an administrative oversight, assuring no market harm occurred. The company has since strengthened its compliance controls to prevent future lapses.

5E Advanced Materials has announced a significant upgrade to its Fort Cady Project, increasing measured and indicated borate resources by 61% and lithium resources by 54%, positioning it as a leading domestic supplier of critical minerals.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

The Supreme Court of Western Australia has approved the share and option schemes for Capricorn Metals’ acquisition of Warriedar Resources, setting the stage for a significant consolidation in the gold exploration sector.

DroneShield Limited has clarified the recent sharp decline in its share price, attributing the market movement to disclosed director share disposals rather than any undisclosed material information.

Anteris Technologies has gained FDA approval to start patient recruitment in the US for its pivotal PARADIGM Trial, following initial European regulatory success. The company advances manufacturing and clinical readiness as it pushes toward key regulatory milestones.